Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Marks

Showing results (721-730 of 986) with videos related to

Pageof 99
Sort By:
Assay and Drug Development Technologies|April 20, 2004
A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrateBryan D Marks, Ronald W Smith, Heidi A Braun, et al.
Biosensors & Bioelectronics|August 1, 2009
Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodiesMarvin G Warner, Jay W Grate, Abby Tyler, et al.
Analytical Chemistry|June 18, 2009
Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivityRichard M Ozanich, Cynthia J Bruckner-Lea, Marvin G Warner, et al.
Journal of Immunological Methods|June 9, 2004
Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodiesYper H J Hall, John A Chaddock, Hilary J Moulsdale, et al.
British Journal of Haematology|September 1, 1994
Characterization of human blood group scFv antibodies derived from a V gene phage-display libraryN C Hughes-Jones, B D Gorick, J M Bye, et al.
Transplantation|July 24, 2012
Distribution of ABO blood group antibody titers in pediatric patients awaiting renal transplantation: implications for organ allocation policyA Nicholas R Barnett, Alex Hudson, Vassilis G Hadjianastassiou, et al.
Nature Biotechnology|December 19, 2006
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxinConsuelo Garcia-Rodriguez, Raphael Levy, Joseph W Arndt, et al.
Nephron|September 21, 2017
UK Renal Registry 19th Annual Report: Chapter 9 Clinical, Haematological and Biochemical Parameters in Patients on Renal Replacement Therapy in Paediatric Centres in the UK in 2015: National and Centre-specific AnalysesAlexander J Hamilton, Fiona Braddon, Anna Casula, et al.
Pediatric Nephrology (Berlin, Germany)|September 18, 2017
Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodiesJon Jin Kim, Olivia Shaw, Chloe Martin, et al.
Nature Communications|June 23, 2026
A belt-buckle checkpoint regulates the onset of botulinum neurotoxin intoxicationBaohua Chen, Linfeng Gao, Melvin Bönninger, et al.
Pageof 99

Showing results (721-730 of 986) with videos related to

Sort By:
Pageof 99
Assay and Drug Development Technologies|April 20, 2004
A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrateBryan D Marks, Ronald W Smith, Heidi A Braun, et al.
Biosensors & Bioelectronics|August 1, 2009
Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodiesMarvin G Warner, Jay W Grate, Abby Tyler, et al.
Analytical Chemistry|June 18, 2009
Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivityRichard M Ozanich, Cynthia J Bruckner-Lea, Marvin G Warner, et al.
Journal of Immunological Methods|June 9, 2004
Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodiesYper H J Hall, John A Chaddock, Hilary J Moulsdale, et al.
British Journal of Haematology|September 1, 1994
Characterization of human blood group scFv antibodies derived from a V gene phage-display libraryN C Hughes-Jones, B D Gorick, J M Bye, et al.
Transplantation|July 24, 2012
Distribution of ABO blood group antibody titers in pediatric patients awaiting renal transplantation: implications for organ allocation policyA Nicholas R Barnett, Alex Hudson, Vassilis G Hadjianastassiou, et al.
Nature Biotechnology|December 19, 2006
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxinConsuelo Garcia-Rodriguez, Raphael Levy, Joseph W Arndt, et al.
Nephron|September 21, 2017
UK Renal Registry 19th Annual Report: Chapter 9 Clinical, Haematological and Biochemical Parameters in Patients on Renal Replacement Therapy in Paediatric Centres in the UK in 2015: National and Centre-specific AnalysesAlexander J Hamilton, Fiona Braddon, Anna Casula, et al.
Pediatric Nephrology (Berlin, Germany)|September 18, 2017
Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodiesJon Jin Kim, Olivia Shaw, Chloe Martin, et al.
Nature Communications|June 23, 2026
A belt-buckle checkpoint regulates the onset of botulinum neurotoxin intoxicationBaohua Chen, Linfeng Gao, Melvin Bönninger, et al.
Pageof 99